Cancer remains a major killer that impacts a large number of new patients every year. One leading reason for cancer is an inappropriate response to DNA damage. Upon DNA damage, the cell will initiate apoptosis through the mitochondria apparatus when DNA damage is beyond repair. Once this cell death pathway is triggered, cytotoxic factors are released from mitochondria to activate caspases that induce apoptosis. An impaired apoptotic potential of damaged cells leads to continued cell division without restriction that frequently develops into cancer. Indeed, mis-regulation of apoptosis is associated with many cancers. Understanding the molecular mechanisms that regulate DNA damage signals and how they are transmitted to mitochondria to initiate apoptosis is therefore important for cancer research. Biochemical approaches are utilized to reconstitute DNA damage-induced apoptosis. Degradation of Mcl-1, a key anti-death protein, is required to trigger cytochrome c release from mitochondria upon DNA damage. Mcl-1 is degraded through the ubiquitin-proteasome pathway. In the ubiquitin-proteasome system, the ubiquitin ligases determine the specificity and timing of substrates destruction. A biochemical assay was established to search for such enzyme from human cell extracts, and a novel ubiquitin ligase Mule (Mcl-1 ubiquitin ligase e3) was cloned. Mule promotes ubiquitin modification of Mcl-1 through direct interaction through a BH3 domain, and Mule is indispensable for Mcl-1 mediated apoptotic pathway. Besides Mcl-1, Mule also ubiquitinates other substrates including p53, thus adding another intriguing link to the apoptosis pathway. In this proposal, the mechanism by which Mule activation and the differential regulation of Mule target different substrates in response to DNA damage signals will be investigated. The biological function of Mule in DNA damage response will be studied in Aim 1. Our newly generated Mule knockout mouse embryonic fibroblast cells will be utilized to study the function of Mule in DNA damage induced apoptosis and cell cycle checkpoints. We will also investigate the structure and function relationship of Mule, especially the requirement of the ubiquitin ligase activity of Mule for its function in DNA damage response in this aim. We will characterize the ubiquitination and degradation of Mcl-1 and p53 by Mule in Aim 2. Ubiquitin chain formation, E3 activity (Mule versus Mdm2), the contribution of Mcl-1 and p53 in Mule-dependent DNA damage response, and regulatory mechanisms of Mcl-1 and p53 ubiquitination will be investigated in this aim.
In Aim 3, we will further characterize the interaction of Mule with its substrates;especially map the binding site of p53 to Mule. We will study how the interaction between Mule and substrates are regulated by DNA damage. More importantly, we will search for novel protein factors modulating Mule acitivity through tandem affinity purification.
In Aim 4, we will put more focus on post- translation modification of Mule, especially phosphorylation of Mule in DNA damage response and discuss potential mechanisms involved in it. These experiments should reveal novel mechanisms mediating DNA damage signals and how they are transduced through Mule, thereby providing fundamental insights into regulatory networks controlling apoptosis and DNA damage response. A mechanistic understanding of this pathway will help us decipher how apoptosis is deregulated in cancer and potentially identify new targets for therapeutic intervention.

Public Health Relevance

Misregulation of apoptosis is considered to be one of the major mechanisms for tumorigenesis, especially upon exposure to exogenous DNA damaging agents and during normal physiological processes. This proposal will disclose a novel mechanism mediating DNA damage signals, thereby providing fundamental insights into regulatory networks controlling apoptosis. A mechanistic understanding of this pathway will help us decipher how apoptosis is deregulated in cancer and potentially identify new targets for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA133228-06
Application #
8769278
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Hildesheim, Jeffrey
Project Start
2009-01-01
Project End
2014-11-30
Budget Start
2013-11-19
Budget End
2014-11-30
Support Year
6
Fiscal Year
2013
Total Cost
$237,614
Indirect Cost
$82,816
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Zhang, Jing; Zhong, Qing (2014) Histone deacetylase inhibitors and cell death. Cell Mol Life Sci 71:3885-901
Tang, Zaiming; Zhu, Muyuan; Zhong, Qing (2014) Self-eating to remove cilia roadblock. Autophagy 10:379-81
Tang, Zaiming; Lin, Mary Grace; Stowe, Timothy Richard et al. (2013) Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar satellites. Nature 502:254-7
Yan, Xianghua; Sun, Qiming; Ji, Jian et al. (2012) Reconstitution of leucine-mediated autophagy via the mTORC1-Barkor pathway in vitro. Autophagy 8:213-21
Chen, Dandan; Fan, Weiliang; Lu, Yiting et al. (2012) A mammalian autophagosome maturation mechanism mediated by TECPR1 and the Atg12-Atg5 conjugate. Mol Cell 45:629-41
Sun, Qiming; Zhang, Jing; Fan, Weiliang et al. (2011) The RUN domain of rubicon is important for hVps34 binding, lipid kinase inhibition, and autophagy suppression. J Biol Chem 286:185-91
Wilz, Livia; Fan, Weiliang; Zhong, Qing (2011) Membrane curvature response in autophagy. Autophagy 7:1249-50
Fan, Weiliang; Nassiri, Ashley; Zhong, Qing (2011) Autophagosome targeting and membrane curvature sensing by Barkor/Atg14(L). Proc Natl Acad Sci U S A 108:7769-74
Zhang, Jing; Kan, Shu; Huang, Brian et al. (2011) Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev 25:2610-8
Sun, Qiming; Westphal, Wiebke; Wong, Kwun Ngok et al. (2010) Rubicon controls endosome maturation as a Rab7 effector. Proc Natl Acad Sci U S A 107:19338-43

Showing the most recent 10 out of 11 publications